



**Date 30 May 2017**

**Sydney, Australia**

## **ASX: NOX**

**Noxopharm  
Limited**

ABN 50 608 966 123

### **Registered Office:**

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

### **Operations Office:**

Suite 3 Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

### **Board of Directors**

#### **Mr Peter Marks**

Chairman  
Non-Executive  
Director

#### **Dr Graham Kelly**

Chief Executive  
Officer  
Managing Director

#### **Dr Ian Dixon**

Non-Executive  
Director

## **RELEASE OF NEW CORPORATE PRESENTATION**

- **7x NOX66 clinical studies in place by end-2017**
- **on schedule for NOX66 efficacy data by end-2017**
- **timetable has registration studies commencing 2018**

30 May 2017: Noxopharm Limited (ASX: NOX) today posts its latest corporate presentation ahead of its program of Mid-Year Briefings commencing today in Melbourne. Those briefings are open to the public.

Dr Kelly, Noxopharm CEO, said, "The most realistic way we can make a meaningful difference right now to the outlook for patients with most forms of aggressive cancer is to make existing chemotherapy and radiotherapy work better. We believe that our front-line drug, NOX66, is the first drug to come into the clinic with a realistic chance of having that effect."

"This new presentation explains how we are going about proving that, the timetable we are working to that aims to be in registration studies by the end of 2018, and the infrastructure that we are putting in place to support the anticipated growth."

The presentation (with video) is accessed by the following link:

[http://www.finnewsnetwork.com.au/Presentations/Noxopharm/Noxopharm\\_May\\_2017\\_Mid\\_Year\\_Briefing](http://www.finnewsnetwork.com.au/Presentations/Noxopharm/Noxopharm_May_2017_Mid_Year_Briefing)

### Timetable for Mid-Year Briefings:

#### **Melbourne: Tuesday May 30:**

Location: Radisson on Flagstaff Gardens 380 William St, Melbourne Time: 11am - 12.30pm

#### **Sydney: Friday June 2:**

Location: Sofitel Sydney Wentworth 61-101 Phillip St, Sydney Time: 1pm - 2.30pm

#### **Gold Coast: Tuesday June 6:**

Location: Surfers Paradise Marriott Resort Hotel, 158 Ferny Ave, Surfers Paradise Time: 1.30pm - 3.00pm

### **About NOX66**

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour.

Idronoxil is a kinase inhibitor that works by inhibiting a range of enzymes including sphingosine kinase and PI3 kinase that regulate cell pro-survival mechanisms and which are over-expressed in cancer cells, as well as inhibiting external NADH oxidase Type 2 (ENOX 2) which is responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane of cancer cells and whose expression is limited to cancer cells. Inhibition of these enzymes results in disruption of key downstream pro-survival mechanisms including resistance mechanisms, sensitizing the cancer cell to the cytotoxic effects of chemotherapy drugs and radiotherapy.

### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

**INVESTOR AND MEDIA ENQUIRIES: Prue Kelly**

**E: [info@noxopharm.com](mailto:info@noxopharm.com)      T: + 61 2 9144 2223**

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.